Hypoglycemia and Cardiac Arrhythmias in Type 1 Diabetes

2019-05-23 20:21:33 | BioPortfolio


The investigators hypothesise that patients with type 1 diabetes have clinically relevant, but often unrecognised, episodes of arrhythmias linked to episodes of hypoglycaemia and/or clinically significant fluctuations in plasma glucose. Furthermore, the investigators hypothesise that following episodes of hypoglycaemia, rebound hyperglycaemia may result in a prolonged period of increased QTc and, thereby, increased susceptibility to serious cardiac arrhythmias.


In this study, changes in cardiac rhythm, haemodynamic regulation, and hormonal response will be evaluated during insulin-induced hypoglycaemia followed by hyperglycaemia and euglycaemia, respectively, on two separate experimental days. Twenty-four patients with type-1 diabetes are included. Patients are randomised 1:1 to start with either the combined hypo- and hyperglycaemic or the hypo- and euglycaemic clamp. After an overnight 10 hour fast, participants are admitted for a 255 minute clamp. An individualised insulin infusion will be initiated targeting a plasma glucose level of 5.0-8.0 mmol/l. When the targeted plasma glucose level is achieved, the hyperinsulinaemic euglycaemic clamp will be initiated at time 0. The insulin infusion will be fixed at an infusion rate 80 mU/m2/min and a 20% glucose infusion will be initiated in order to regulate plasma glucose levels. After 45 min of monitoring at euglycaemic plasma glucose level, plasma glucose will be decreased over a period of 30 minutes, targeting 2.5 mmol/l for a period of 60 min in a hyperinsulinaemic hypoglycaemic clamp. From 135 min to 195 min, plasma glucose levels will be increased to either hyperglycaemic level (20mmol/l) or normoglycaemic (6mmol/L) and will be kept constant for 105 minutes. Echocardiography is performed at baseline, at hypoglycaemic level and at hyper-or normoglycaemic level. Blood samples are taken every 15 minutes throughout the entire clamp, however bedside plasma glucose is analysed every fifth minute. A Holter-ECG is obtained throughout the entire clamp.

Study Design


Diabetes type1


Hypoglycemic combined with either normo or hyperglycemic clamp.


Clinical Metabolic Physiology, SDCC


Active, not recruiting


Steno Diabetes Center Copenhagen

Results (where available)

View Results


Published on BioPortfolio: 2019-05-23T20:21:33-0400

Clinical Trials [1866 Associated Clinical Trials listed on BioPortfolio]

Glucose Clamp Study to Prove Hypo- and Hyperglycemic Episodes Using a Non-invasive Glucose Monitoring Device

Continuous monitoring of the skin tissue glucose concentration on two different study days using glucose sensors that work on the principle of impedance spectroscopy, with systematic alter...

Use of a Hyperinsulinemic-hypyglycemic Clamp to Study Hypoglycemia: a Method Development Study

A hyperinsulinemic-hypoglycemic clamp is an experimental procedure, which allows for hypoglycemia to be studied in a safe and controlled manner. The goal of this study is to establish the ...

An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic Clamp

The objective of the study is to evaluate change in insulin secretory capacity in patients with type 2 diabetes mellitus as determined by hyperglycemic clamp after a 28-day oral administra...

The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP

In patients with type 2 diabetes, the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) has lost its insulinotropic activity, but more so after continuous versus bolus ad...

Berberine Hyperglycemic Clamp

Berberine (BBR) is a traditional Chinese medicine used to treat diabetes mellitus for thousands of years in China. The glucose-lowering effect of BBR has been confirmed in numerous studies...

PubMed Articles [4903 Associated PubMed Articles listed on BioPortfolio]

Hospital Admissions for Hyperglycemic Emergencies in Young Adults at an Inner-City Hospital.

There is limited information characterizing young adults (18-35 years) (YA) with diabetes, especially those admitted for hyperglycemic emergencies. The study aims were to examine associations of patie...

Glutaminostatin: another facet of glucagon as a regulator of plasma amino acid concentrations.

Glucagon was first described in 1923 as a hyperglycemic substance found in aqueous pancreas extracts. Since then, it has become well accepted that the major physiological role of glucagon is to increa...

Automatic Detection of Hypoglycemic Events From the Electronic Health Record Notes of Diabetes Patients: Empirical Study.

Hypoglycemic events are common and potentially dangerous conditions among patients being treated for diabetes. Automatic detection of such events could improve patient care and is valuable in populati...

Review: Diabetes, Obesity and Cancer - Pathophysiology and Clinical Implications.

Obesity and diabetes have both been associated with an increased risk of cancer. In the face of increasing obesity and diabetes rates worldwide, this is a worrying trend for cancer rates. Factors such...

Anti-hyperglycemic and anti-hyperlipidemic effects of a special fraction of Luohanguo extract on obese T2DM rats.

Luohanguo (LHG), a traditional Chinese medicine, could clear heat, moisten the lung, soothe the throat, restore the voice, and lubricate intestine and open the bowels. LHG has been utilized for the tr...

Medical and Biotech [MESH] Definitions

An electrophysiologic technique for studying cells, cell membranes, and occasionally isolated organelles. All patch-clamp methods rely on a very high-resistance seal between a micropipette and a membrane; the seal is usually attained by gentle suction. The four most common variants include on-cell patch, inside-out patch, outside-out patch, and whole-cell clamp. Patch-clamp methods are commonly used to voltage clamp, that is control the voltage across the membrane and measure current flow, but current-clamp methods, in which the current is controlled and the voltage is measured, are also used.

A serious complication of TYPE 2 DIABETES MELLITUS. It is characterized by extreme HYPERGLYCEMIA; DEHYDRATION; serum hyperosmolarity; and depressed consciousness leading to COMA in the absence of KETOSIS and ACIDOSIS.

Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.

A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.

A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277)

More From BioPortfolio on "Hypoglycemia and Cardiac Arrhythmias in Type 1 Diabetes"

Quick Search

Relevant Topic

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Searches Linking to this Trial